Inventiva overhauled senior leadership as it heads toward a late-stage decision point for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH). The French biotech named Axel-Sven Malkomes as CFO, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer, replacing prior role holders as Jean Volatier shifts to EVP finance & corporate social responsibility. The personnel changes arrive with the company looking to a Phase III readout scheduled for 4Q26 for lanifibranor. Inventiva’s strategy now hinges on meeting clinical endpoints in MASH, where payer and guideline scrutiny can heavily influence market uptake even after positive efficacy signals. The revamped C-suite suggests the company is prioritizing operational readiness and governance as it approaches the most execution-sensitive phase of its development timeline.